Seres Therapeutics Inc (OQ:MCRB)
Business Focus: Bio Therapeutic Drugs
Apr 09, 2024 07:00 am ET
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting bloodstream infections, including those that may harbor antibiotic resistance. Infections are a leading cause of mortality and morbidit
Mar 28, 2024 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to Marella Thorell, the Company’s new Executive Vice President and Chief Financial Officer, consisting entirely of stock options.
Mar 19, 2024 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 13, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 shares of its common stock.
Mar 05, 2024 07:00 am ET
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.
Feb 28, 2024 07:00 am ET
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update.
Feb 27, 2024 07:00 am ET
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET.
Feb 26, 2024 07:00 am ET
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz’s retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition.
Jan 17, 2024 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units (“RSUs”) covering 22,500 shares of its common stock.
Jan 09, 2024 08:31 am ET
Thinking about buying stock in Grifols, Esperion Therapeutics, Rithm Capital, Applied Optoelectronics, or Seres Therapeutics?
NEW YORK, Jan. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRFS, ESPR, RITM, AAOI, and MCRB.
Jan 09, 2024 07:00 am ET
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 1
Jan 04, 2024 04:00 pm ET
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT.
Dec 07, 2023 07:46 pm ET
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematol
Nov 28, 2023 09:18 am ET
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET.
Nov 21, 2023 05:00 am ET
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trillions of cells
Nov 11, 2023 08:27 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Seres Therapeutics, Inc. (NASDAQ: MCRB) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Seres Therapeutics, Inc. (NASDAQ: MCRB) (“Seres”) on behalf of the company’s investors. Since June 2023, shares of Seres’ common stock have declined in value from a trading price of over $5.00...
Nov 02, 2023 07:00 am ET
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial results show strong continued progress, driven by a significant increase in new patient starts
Nov 01, 2023 11:37 pm ET
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Seres Therapeutics, Inc.; Urges Seres Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Seres’s board of directors (the “Board”) has violated its...
Nov 01, 2023 10:30 am ET
Flagship Pioneering Launches Pioneering Intelligence
CAMBRIDGE, Mass., Nov. 1, 2023 /PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate innovation in the life sciences and beyond. Flagship marked the official launch of Pioneering Intelligence with an AI Summit that drew tech and life sciences leaders from around the globe for a day long series of talks. Initiated in 2021, Pioneering Intelligence will augment the capabilities of Flagship companies, drive AI and machine learning (ML) innovation, and originate new platform companies
Oct 30, 2023 05:30 pm ET
Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET.
Oct 12, 2023 07:00 am ET
Seres Therapeutics to Highlight VOWST™ Data at IDWeek
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023), including two posters of post-hoc analyses from the ECOSPOR III and ECOSPOR IV Phase 3 trials, which supported the recent approval by the US Food and Drug Administration (FDA)
Oct 06, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on October 4, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 3,000 shares of its common stock to two new employees, consisting of stock options to purchase an aggregate of 1,500 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 1,500 shares of its common stock.
Sep 11, 2023 06:30 am ET
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy.
Sep 08, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on September 6, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 91,000 shares of its common stock to two new employees, consisting of stock options to purchase an aggregate of 45,500 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 45,500 shares of its common stock.
Sep 07, 2023 10:00 am ET
Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m. ET.
Aug 08, 2023 07:00 am ET
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2023 financial results and provided business updates.
Aug 04, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on July 31, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 1950 shares of its common stock to one new employee, consisting of stock options to purchase 975 shares of common stock and restricted stock units (“RSUs”), covering 975 shares of its common stock.
Aug 01, 2023 07:00 am ET
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a general business update.
Aug 01, 2023 07:00 am ET
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 3:00 p.m. ET.
Jul 14, 2023 04:01 pm ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on July 13, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 66,066 shares of its common stock to seven new employees, consisting of stock options to purchase an aggregate of 30,033 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 30,033 shares of its common stock.
Jun 21, 2023 09:00 am ET
Seres Therapeutics Named to TIME100 Most Influential Companies List
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 companies making an extraordinary impact around the world. Seres was included within the ‘
Jun 17, 2023 03:45 pm ET
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Scie
Jun 09, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 7, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 19,400 shares of its common stock to six new employees, consisting of stock options to purchase an aggregate of 9,700 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 9,700 shares of its common stock.
Jun 09, 2023 07:00 am ET
Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres Therapeutics management, will participate in a question and answer format discussion at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 4:40 p.m. PT.
Jun 05, 2023 07:00 am ET
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Diffi
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Scie
Jun 02, 2023 07:00 am ET
Seres Therapeutics to Present at Jefferies Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ET in New York City.
May 30, 2023 04:00 pm ET
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores, live-brpk), an orally administered microbiota-bas
May 16, 2023 06:00 am ET
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit
May 10, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 3, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 19,000 shares of its common stock to four new employees, consisting of stock options to purchase an aggregate of 11,000 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 8,000 shares of its common stock.
May 09, 2023 07:00 am ET
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.
May 09, 2023 07:00 am ET
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155. SER-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune toleran
May 08, 2023 07:00 am ET
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the
Seres Therapeutics, Inc. (Nasdaq: MCRB), and Nestlé Health Sci
May 05, 2023 07:00 am ET
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology resu
Apr 27, 2023 07:00 am ET
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a new $250 million senior secured debt facility (“Term Loan Facility”) provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The Company drew the first tranche of $110 million at closing,
Apr 26, 2023 07:46 pm ET
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacter
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Scie
Apr 07, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on April 5, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 22,000 shares of its common stock to three new employees, consisting of stock options to purchase an aggregate of 11,000 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 11,000 shares of its common stock.
Mar 09, 2023 07:00 am ET
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.
Mar 07, 2023 07:00 am ET
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.
Mar 03, 2023 04:00 pm ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 15,500 shares of its common stock to three new employees, consisting of stock options to purchase an aggregate of 9,250 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 6,250 shares of its common stock.
Feb 28, 2023 07:00 am ET
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update.
Feb 27, 2023 07:00 am ET
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET.
Feb 14, 2023 07:00 am ET
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of data from its Phase 3 ECOSPOR IV trial (ClinicalTrials.gov Identifier:
Feb 08, 2023 07:28 am ET
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway. SER-155, an investigational oral microbiome therapeutic, is designed to reduce the incidence of gastrointestinal (GI) infections, bloodstream infections, and graft
Feb 03, 2023 11:30 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on February 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its common stock to eleven new employees, consisting of stock options to purchase an aggregate of 32,500 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 16,250 shares of its common stock.
Jan 13, 2023 07:00 am ET
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees, consisting of stock options to purchase an aggregate of 9,000 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 4,500 shares of its common stock.
Jan 05, 2023 07:00 am ET
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres’ Board, effective immediately.
Jan 04, 2023 07:00 am ET
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.
Nov 22, 2022 04:01 pm ET
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30
Nov 02, 2022 07:00 am ET
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business updates.
Oct 27, 2022 07:00 am ET
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m. ET to discuss third quarter 2022 results and provide a general business update.
Oct 26, 2022 07:00 am ET
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI). T
Oct 23, 2022 03:30 pm ET
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the presentation of safety and efficacy data from its open-label Phase 3 ECOSPOR IV extension study evaluating investigational oral microbiome therapeutic SER-109 for the prevention of rCDI at the IDWeek 2022 and American College of Gastro
Oct 19, 2022 02:00 pm ET
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the
Oct 12, 2022 07:00 am ET
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will be presenting data from its ECOSPOR IV trial of SER-109, an investigational microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI), at two leading industry conferences: IDWeek 2022 (W
Sep 23, 2022 09:31 am ET
Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics?
NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RUBY, NXPL, MCRB, SAVA, and TCRT.
Sep 08, 2022 07:00 am ET
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland. Dr. Henn will present at 12:00 p.m. ET to
Sep 07, 2022 07:00 am ET
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI). SER-109 is a
Aug 04, 2022 07:00 am ET
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET.
Aug 03, 2022 07:00 am ET
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2022 financial results and provided business updates.
Jul 28, 2022 07:00 am ET
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m. ET to discuss second quarter 2022 results and provide a general business update.
Jun 30, 2022 07:30 am ET
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into securities purchase agreements with new and existing investors and certain directors and officers in a registered direct offering of 31,746,030 shares of common stock (the “Shares”) at a purchase price of $3.
Jun 07, 2022 07:00 am ET
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109
Jun 01, 2022 07:00 am ET
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiatio
May 23, 2022 08:00 am ET
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz...
May 22, 2022 03:15 pm ET
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut
May 10, 2022 07:00 am ET
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the
May 04, 2022 07:00 am ET
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.
Apr 28, 2022 07:00 am ET
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
Seres Therapeutics, Inc. (NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update.
Mar 18, 2022 07:00 am ET
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplan
Mar 10, 2022 07:00 am ET
Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 8:00 a.m. ET.
Mar 03, 2022 07:00 am ET
Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET.
Mar 01, 2022 07:00 am ET
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided business updates.
Feb 28, 2022 08:00 am ET
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of
Feb 22, 2022 07:00 am ET
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021 results and provide a general business update.
Feb 22, 2022 07:00 am ET
Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 2:00 p.m. ET.
Feb 15, 2022 09:05 am ET
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.
Feb 08, 2022 07:00 am ET
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer effective February 7, 2022, reporting directly to Eric Shaff, President and Chief Executive Officer.
Jan 24, 2022 07:00 am ET
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022, from 8:30 a.m. to 10:00 a.m. ET.
Jan 19, 2022 05:01 pm ET
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile inf
Jan 04, 2022 07:00 am ET
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m. ET.
Dec 16, 2021 07:00 am ET
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). Following the topline clinical data readout in July, which noted that the SER-287 Ph
Nov 30, 2021 07:00 am ET
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Ve
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that the first patient has been enrolled in the SER-155 Phase 1b study. SER-155 is an investigational, oral, cultivated microbiome therapeutic. The consortia is a rationally-designed selection of bacteria optimized to enhance desired
Nov 24, 2021 07:00 am ET
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – De
Nov 10, 2021 07:00 am ET
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2021 financial results and provided business updates.
Nov 10, 2021 02:00 am ET
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics, a leading microbiome therapeutics company, announced today a collaboration to manufacture SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI). Under the terms of the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza’s Ibex® campus in Visp, Switzerland.
Nov 04, 2021 07:00 am ET
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m. ET to discuss third quarter 2021 results and provide a general business update.
Oct 26, 2021 07:00 am ET
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scienti
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). New data from an exploratory analysis demonstrate SER-109 re
Oct 13, 2021 10:00 am ET
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
CAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Oct 02, 2021 01:15 pm ET
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). SER-109 was associated with significantly greater reduction
Sep 29, 2021 02:00 pm ET
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI), will be presented at the IDWeek 2021 Virtual Conference (Sept. 29-Oct. 3). The
Sep 15, 2021 07:00 am ET
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). The target enrollment of a minimum
Sep 07, 2021 07:00 am ET
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in three upcoming investor conferences:
Aug 05, 2021 07:00 am ET
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a discussion at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 9:00 a.m. ET.
Aug 03, 2021 07:00 am ET
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates.
Jul 29, 2021 07:00 am ET
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m. ET to discuss second quarter 2021 results and provide a general business update.
Jul 22, 2021 10:51 am ET
Thinking about buying stock in PainReform, Norwegian Cruise Line, Seres Therapeutics, CSX Corp, or Neptune Wellness Solutions?
NEW YORK, July 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRFX, NCLH, MCRB, CSX, and NEPT.
Jul 22, 2021 09:31 am ET
Thinking about buying stock in Hyzon Motors, Costamare, RealReal, Tri Pointe Homes, or Seres Therapeutics?
NEW YORK, July 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYZN, CMRE, REAL, TPH, and MCRB.
Jul 22, 2021 07:33 am ET
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).
Jul 22, 2021 07:00 am ET
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet its primary endpoint of improving clinical remission rates compared to placebo. Bo
Jul 01, 2021 07:00 am ET
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic.
Jun 14, 2021 07:51 pm ET
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security I
CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.
Jun 10, 2021 07:00 am ET
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis (UC) on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.
Jun 10, 2021 07:00 am ET
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics, will present at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:00 p.m. ET.
Jun 04, 2021 02:30 pm ET
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln, Germany) demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is associated with poor clinical o
Jun 01, 2021 08:00 am ET
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic desig
May 25, 2021 08:00 am ET
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will present a corporate overview at two upcoming investor conferences:
May 21, 2021 12:15 pm ET
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 20
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI). The data presented today in a poster o
May 20, 2021 08:00 am ET
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres.
May 19, 2021 05:22 pm ET
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncol
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021. In an or
May 12, 2021 07:00 am ET
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
Seres Therapeutics, Inc., (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.
May 11, 2021 08:00 am ET
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present recent research findings from its microbiome drug development portfolio at Digestive Disease Week® (DDW), which is taking place virtually from May 21-23, 2021. With two oral presentations and two poste
May 04, 2021 07:00 am ET
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported first quarter 2021 financial results and provided business updates.
Apr 28, 2021 07:00 am ET
Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2021 at 8:30 a.m. ET to discuss first quarter 2021 results and provide a general business update.
Apr 15, 2021 07:00 am ET
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.
Mar 12, 2021 07:00 am ET
Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16 at 9:20 a.m. ET.
Mar 08, 2021 07:00 am ET
Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company, in collaboration with study partners, The Parker Institute for Cancer Immunotherapy (PICI) and The University of Texas MD Anderson Cancer Center, has voluntarily discontinued further enrollment in the Melanoma Checkpoint and Gut Microbiome Alteration With Mic
Mar 02, 2021 07:00 am ET
Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis
“People with ulcerative colitis and other inflammatory bowel diseases are in need of safe and effective treatment options, especially for mild-to-moderate forms of the disease. ECO-RESET achieved its target enrollment even amid the ongoing COVID-19 pandemic, a reflection of this high unmet need,” said Lisa von Moltke, M.D., Chief Medical Officer of Seres. “We believe microbiome therapeutics offer the potential for an alternative treatment approach for inflammatory bowel diseases and have been committed to advancing microbiome therapeutics to address this need. We’re pleased that SER-287, our m
Mar 02, 2021 07:00 am ET
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided business updates.
Feb 26, 2021 08:00 am ET
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences:
Feb 25, 2021 06:00 am ET
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds and accounts managed by BlackRock, The Baupost Group, Banque Pictet on behalf of their clients and eight other investors alongside Flagship Pioneering.
Feb 24, 2021 07:00 am ET
Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that management will host a conference call and live audio webcast on March 2, 2021 at 8:3
Jan 19, 2021 07:00 am ET
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI). The data presentation, entitled “Microbiome
Jan 06, 2021 07:00 am ET
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company’s Phase 1b trial of SER-287 in patients with active mild-to-moderate ulcerative colitis (UC), most of whom were failing current therapies. The study results demonstrated that SER-287 administration was associated with positive
Jan 06, 2021 07:00 am ET
Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.
Nov 19, 2020 07:00 am ET
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences:
Nov 09, 2020 07:00 am ET
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported financial results from the third quarter ended September 30, 2020, and provided business updates.
Nov 06, 2020 07:00 am ET
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation centr
Nov 02, 2020 07:00 am ET
Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that management will host a conference call and live audio webcast on November 9, 2020 at
Oct 22, 2020 07:00 am ET
Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO).
Oct 12, 2020 07:00 am ET
Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the presentation of previously announced positive Phase 3 results from the ECOSPOR III trial of SER-109 at the Virtual American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 23-28, 2020. New data to be presented in Seres’ late-breaker
Sep 22, 2020 07:00 am ET
Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T.
Sep 14, 2020 07:00 am ET
Seres Therapeutics to Present at Upcoming Investor Conferences
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:
Sep 11, 2020 07:00 am ET
Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile
Aug 17, 2020 04:15 pm ET
Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced the closing of an underwritten public offering of 12,075,000 shares of its common stock, at a public offering price of $21.50 per share, before underwriting discounts and commissions, and including the exercise in full of the underwriters’ option to purchase an additional 1,575,000 shares of common stock. The net proceeds from
Aug 12, 2020 09:39 pm ET
Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, at a public offering price of $21.50 per share, before underwriting discounts and commissions. Seres also granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its common stock on the same terms and co
Aug 11, 2020 05:48 pm ET
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Seres Therapeutics, Inc. (Nasdaq:MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced that it is commencing an underwritten registered public offering of 8,000,000 shares of its common stock. As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock on the same terms and conditions. The proposed offering is subject to mar
Aug 10, 2020 06:30 am ET
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study showed that SER-109 administration resulted in a highly statistically significant
Jul 28, 2020 07:00 am ET
Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results from the second quarter ended June 30, 2020, and provided an operational update.
Jul 07, 2020 08:00 am ET
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.
Jun 22, 2020 07:00 am ET
Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Young brings to Seres over 20 years of commercial and marketing leadership experience, having successfully led the growth of several i
Jun 02, 2020 04:00 pm ET
Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 9th at 2:10 p.m. ET.
May 28, 2020 08:00 am ET
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
CAMBRIDGE, Mass., May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
May 28, 2020 08:00 am ET
Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET.
May 18, 2020 07:00 am ET
Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual webcast symposium focused on SER-109 as a potential new therapeutic option for recurrent Clostridioides difficile infection (CDI) on Wednesday, May 27, 2020 from 8:30 to 9:30 a.m. ET.
May 07, 2020 07:00 am ET
Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results from the first quarter ended March 31, 2020 and provided an operational update.
Apr 30, 2020 07:00 am ET
Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on May 7, 2020 at 8:30 a.m. ET to discuss first quarter 2020 results and provide a general business update.
Apr 06, 2020 07:00 am ET
Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer
Seres Therapeutics, Inc., (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership positions at Alkermes, Sanofi Genzyme and Millennium Pharmaceuticals/Takeda Oncology.
Mar 30, 2020 07:00 am ET
Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates
Seres Therapeutics, Inc., (Nasdaq: MCRB) announced today that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III. SER-109 is an oral, first-in-field microbiome therapeutic candidate that has been granted Orphan Drug and Breakthrough Therapy designations by the U.S. Food and Drug Administration (
Mar 23, 2020 07:00 am ET
Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Paul Biondi, Executive Partner at Flagship Pioneering, to its Board of Directors. Noubar Afeyan, Ph.D., a co-founder of Seres and Chief Executive Officer of Flagship Pioneering, is stepping down after serving on the Board since the Company’s founding.
Mar 15, 2020 03:00 pm ET
Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit
Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the virtual Chardan Microbiome Medicines Summit on Monday, March 16 at 8:15 a.m. ET.
Mar 13, 2020 07:00 am ET
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation
Seres Therapeutics, Inc. (Nasdaq: MCRB) today provided a statement on a safety
Mar 02, 2020 07:00 am ET
Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights
Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported fourth quarter and full year 2019 financial results and provided an operational update.
Feb 25, 2020 04:00 pm ET
Seres Therapeutics to Present at the Cowen 2020 Health Care Conference
Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET.
Feb 25, 2020 07:00 am ET
Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020
Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that management will host a conference call and live audio webcast on March 2, 2020 at 8:30 a.m. ET to discuss fourth quarter and full year 2019 results and provide a general business update.
Dec 16, 2019 07:00 am ET
Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors. Roger Pomerantz, M.D., has decided to step down after serving as Chairman of the Board since 2013. Dr. Pomerantz will continue to serve as an advisor to Seres.
Nov 14, 2019 07:00 am ET
Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET.
Nov 05, 2019 07:00 am ET
Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results for the three months ended September 30, 2019 and provided a business update.
Oct 31, 2019 04:00 pm ET
Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general business update.
Aug 06, 2019 07:00 am ET
Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson to its Board of Directors. Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan.
Aug 06, 2019 07:00 am ET
Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported second quarter 2019 financial results and provided business updates.
Aug 01, 2019 07:01 am ET
Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.m. ET.
Aug 01, 2019 07:00 am ET
Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on August 6, 2019 at 8:00 a.m. ET to discuss second quarter 2019 results and provide a general business update.
Jun 19, 2019 07:00 am ET
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
Seres
Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”) today provided a
statement on a safety alert from the U.S. Food and Drug Administration
(FDA) regarding bloodstream infections with multi-drug resistant
organisms (MDROs) transmitted through fecal microbiota transplantation
(FMT). On June 13th, 2019,
Jun 13, 2019 09:23 pm ET
Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, today announced the pricing of an underwritten
public offering of 26,666,667 shares of its common stock, at a public
offering price of $2.25 per share, before underwriting discounts and
commissions. Seres also granted the underwriters a 30-day option to
purchase up to an additional 2,666,666 shares of its common st
Jun 12, 2019 04:07 pm ET
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, today announced that it is commencing an
underwritten registered public offering of $60.0 million of shares of
its common stock. As part of this offering, Seres intends to grant the
underwriters a 30-day option to purchase up to an additional $9.0
million of shares of its common stock. All of the shares in the prop
May 29, 2019 04:00 pm ET
Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will
present at the Jefferies 2019 Healthcare Conference in New York, NY on
Wednesday, June 5th at 2:30 p.m. ET.
May 02, 2019 07:00 am ET
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
Seres
Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) today
reported first quarter 2019 financial results and provided business
updates.
Apr 29, 2019 04:00 pm ET
Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on May 2, 2019 at
8:30 a.m. ET to discuss first quarter 2019 results and provide a general
business update.
Apr 09, 2019 08:50 am ET
Consolidated Research: 2019 Summary Expectations for Wyndham Hotels & Resorts, Apellis Pharmaceuticals, Transcat, Emerald Expositions Events, Capitala Finance, and Seres Therapeutics — Fundamental Ana
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wyndham Hotels & Resorts Inc. (NYSE:WH), Apellis Pharmaceuticals, Inc....
Apr 02, 2019 08:00 am ET
Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced that new
preclinical data supporting the development of microbiome therapeutics
for immuno-oncology (poster title “Leveraging gut microbiota networks to
impact tumor immunotherapy”)1 will be presented by Sceneay et
al. at the 2019 American Assoc
Mar 11, 2019 09:30 am ET
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced a three-year
research collaboration with AstraZeneca. The collaboration will focus on
advancing mechanistic understanding of the microbiome in augmenting the
efficacy of cancer immunotherapy, including potential synergy with
AstraZeneca compounds.
Mar 06, 2019 07:00 am ET
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today reported fourth quarter and
full year 2018 financial results and provided an operational update.
Mar 05, 2019 04:00 pm ET
Seres Therapeutics to Present at Three Upcoming March Conferences
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will
present at each of the following upcoming healthcare conferences:
Mar 04, 2019 07:00 am ET
Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on March 6, 2019 at
8:30 a.m. ET to discuss fourth quarter and full year 2018 results and
provide a general business update.
Feb 07, 2019 09:00 am ET
Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced certain corporate
changes to focus resources on its highest priority, clinical-stage
microbiome therapeutic candidates.
Jan 15, 2019 07:00 am ET
Seres Therapeutics Announces Chief Executive Officer Transition
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of
Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who
is currently Chief Operating and Financial Officer, succeeds Roger J.
Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and
will continue to serve a
Jan 03, 2019 07:00 am ET
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
Seres
Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has
enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating
microbiome development candidate SER-287 in patients with active
mild-to-moderate ulcerative colitis. Seres has received $40 million in
milestone payments associated with th
Nov 28, 2018 08:35 am ET
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Move
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of OraSure Technologies, Inc. (NASDAQ:OSUR), Sierra Wireless, Inc....
Nov 09, 2018 07:00 am ET
Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will
present at the Stifel 2018 Healthcare Conference in New York, NY on
Tuesday, November 13th at 9:30 a.m. ET.
Nov 08, 2018 07:00 am ET
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today reported third quarter 2018
financial results and provided an operational update.
Nov 05, 2018 07:00 am ET
Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on November 8, 2018
at 8:30 a.m. ET to discuss third quarter 2018 results and provide a
general business update.
Oct 22, 2018 07:00 am ET
Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Seres
Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of
Kevin Horgan, M.D., as Executive Vice President and Chief Medical
Officer. Dr. Horgan will lead Seres’ clinical development, clinical
operations, regulatory affairs, and medical affairs functions. Dr.
Horgan will succeed Seres’ outgoing Ch
Oct 18, 2018 08:15 am ET
New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance — Consolidated Revenues, Company Growth, and Ex
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Altair Engineering Inc. (NASDAQ:ALTR), Genomic Health, Inc. (NASDAQ:GHDX),...
Oct 03, 2018 07:00 am ET
Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Seres
Therapeutics, Inc. (Nasdaq:MCRB) today announced it will present new
data for SER-109, a microbiome candidate in Phase 3 development, at the
IDWeek 2018 conference being held from October 3-7 in San Francisco, CA.
The findings, highlighted in two presentations, provide support for
SER-109 as a potential ne
Sep 04, 2018 07:00 am ET
Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
Seres
Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of
Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of
Directors. Ms. Zausner brings decades of financial and operational
leadership experience in the pharmaceutical industry.
Aug 24, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Seres Therapeutics, Barnes & Noble, Carbo Ceramics, BioLife Solutions, CareDx, and Syntel — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Seres Therapeutics, Inc. (NASDAQ:MCRB), Barnes Noble, Inc. (NYSE:BKS),...
Aug 14, 2018 10:07 am ET
The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team
WASHINGTON, Aug. 14, 2018 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) announced today the formation of their coalition which seeks to nurture innovation in microbiome therapeutics and microbiome-based products to address unmet medical needs and bring life-saving treatments to patients. The founding MTIG Board of Directors is comprised of Thomas J. DesRosier, Chairman of the MTIG Board and Executive Vice President, Chief Legal Officer and Secretary of Seres Therapeutics, Lee Jones, MTIG Secretary and Founder, President and Chief Executive Officer of Rebiotix Inc., and
Aug 02, 2018 07:00 am ET
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today reported second quarter 2018
financial results and provided an operational update.
Jul 25, 2018 04:27 pm ET
Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on August 2, 2018 at
8:30 a.m. ET to discuss second quarter 2018 financial results and
provide a general business update.
Jun 19, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Diamondback Energy, Global Net Lease, Ambac Financial Group, IDACORP, Francesca's, and Seres Therapeutics — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diamondback Energy, Inc. (NASDAQ:FANG), Global Net Lease, Inc. (NYSE:GNL),...
Jun 01, 2018 07:00 am ET
Seres Therapeutics to Present at Two Upcoming June Conferences
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at
each of the following upcoming healthcare conferences:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.